Comparing the current results to its competitors, Allurion Technologies Inc reported Revenue decrease in the 1 quarter 2026 year on year by -42.9 %, despite the revenue increase by the most of its competitors of 8.06 %, recorded in the same quarter.
Allurion Technologies Inc , slower than the average decrease reported by the company's competitors of -42.89 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -42.89 %
Allurion Technologies Inc 's Comment on Competition and Industry Peers
Allurion operates in the regulated weight-loss treatment industry, which includes behavioral modification, pharmaceuticals, medical devices, and surgical options. Outside the United States, Allurion competes with regional intragastric balloon manufacturers such as SC MedSil, Medicone, and Spatz Laboratories. Within the United States, three manufacturers have FDA-approved intragastric balloons: Boston Scientific Corporation, Inc. (which acquired Apollo Endosurgery), ReShape Lifesciences, Inc. (now Medtimo), and Spatz FGIA Inc. These competitors' balloons require endoscopy and anesthesia for placement and/or removal. Medtimo does not currently commercialize its product. Allurion also competes with pharmaceutical manufacturers targeting weight loss.
January 24, 2025
Natick, Mass. Allurion Technologies, Inc. (NYSE: ALUR), a company focused on combating obesity, has announced plans to conduct a clinical study that will explore the effects of combining its Allurion Program with GLP-1 agonists to enhance muscle mass and improve overall body composition. GLP-1 therapies, commonly used for weight loss, have previously shown to cause a reduction in lean mass, constituting approximately 40% of the total weight loss experienced by patients.Allurion’s initiative seeks to address this issue by integrating their proprietary program into the treatment regimen, with the goal of optimizing the retention of muscle mass and improving the overall health outcomes for patients undergo...
November 25, 2024
In a bold move to redefine weight loss management, Allurion Technologies, Inc. (NYSE: ALUR) has officially launched AllurionMeds in the United States, an innovative solution designed to combat obesity through the integration of cutting-edge AI technology and essential pharmacological support. The offering combines affordable access to weight loss medications with a distinctive AI-driven platform featuring Coach Iris a virtual assistant that guides users in maintaining their weight long-term, while also providing virtual access to dieticians and utilizing a connected smart scale that tracks not only body weight but also muscle and bone mass. Embracing AI for a Healthier FutureAllurionMeds is positioned at the...
August 6, 2024
Allurion Technologies Faces Challenges in France While Achieving Milestones in Weight Loss and Financial Growth Paris, France Allurion Technologies, Inc. (NYSE: ALUR), a pioneering company focused on combating obesity, has announced a significant decision impacting its operations in France. The company has suspended the sales of its flagship product, the Allurion Balloon, at the request of the French National Agency for the Safety of Medicines and Health Products (ANSM). This suspension will remain in effect pending the implementation of a risk reduction plan related to communication, patient follow-up programs, and the management of post-procedural care.The decision to withdraw the Allurion Balloon from...
January 23, 2024
In an unprecedented move, the Somerset NHS Foundation Trust has become the first non-private sector organization globally, and the first NHS trust in the United Kingdom, to introduce the Allurion Gastric Balloon. Developed by Allurion Technologies, Inc., this innovative approach to weight loss requires neither surgery nor anesthesia, making it a groundbreaking solution in the battle against obesity.Facts:1. The Allurion Gastric Balloon is a unique swallowable device that fills the stomach to induce the feeling of fullness, aiding in weight loss.2. The balloon, once swallowed, remains in the stomach for a specified period, providing a non-invasive alternative that completely eliminates the need for surgery, e...
January 2, 2024
In a significant move to combat obesity, Allurion Technologies, Inc. has announced an expanded commercial agreement with Weight Doctors, Germany s leading group of private clinics and centers for weight loss. This partnership comes on the heels of Allurion s successful year, during which it served over 2,000 patients through its state-of-the-art Virtual Care Suite (VCS) digital platform. Additionally, the company has appointed Brian Conyer to spearhead the commercialization of its rapidly growing digital assets. Let s delve into the details and assess the impact of these developments on Allurion.Expansion of Commercial Agreement with Weight Doctors:Allurion s collaboration with Weight Doctors marks a signifi...
Publicly Traded Peers of Allurion Technologies Inc
Guided Therapeutics Inc Share Performance
-53.70%
This Year
Guided Therapeutics Inc
Profile
Guided Therapeutics Inc operates on a business model focused on developing and commercializing medical devices for the early detection and monitoring of diseases, with a particular emphasis on cervical cancer.
Escalon Medical Corp is a medical technology company that operates through three segments: ophthalmic diagnostics, ophthalmic surgical and ambulance services. They develop, manufacture and sell a range of medical devices and provide EMS billing services to healthcare providers.
Dexcom Incs business model focuses on developing and selling continuous glucose monitoring systems for diabetes management. Their products provide real-time glucose level tracking, enabling users to better manage their condition through data-driven insights.
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Becton Dickinson and Company operates a business model focused on developing and providing advanced medical technologies, including a diverse portfolio of medical devices and diagnostic products. Their strategy emphasizes innovation, quality, and strategic partnerships to enhance patient care and streamline healthcare processes across various settings.
Sources:
Allurion Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Allurion Technologies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
